When to consider dose reduction In some cases, stepping back down to a previous dose is the right move
While these conversations have fueled demand, many of the claims circulating online remain largely unproven in human studies
[Related: See our full Peptide Therapy Series] Rudy Commentary Epithalon is one of the more intriguing peptides in longevity medicine because it targets telomere biology, a mechanism closely tied to cellular aging
Its research profile is different from GHK-Cu, but the two can be discussed in the same broader tissue matrix category
The researchers commented that DSIP exerts stimulating influence upon the superoxid-dismutese, catalase, ceruloplasmin activities as well as the level of nonenzymatic antioxidants--urea and uric acids, because during organism aging the antioxidant defense systems are being suppressed
During the July meeting, FDA reviewers raised concerns about the limited human clinical evidence supporting BPC-157s safety and effectiveness